



PPL/CS/SE/1412 /2011

Date: - 4th April, 2011

To

The Bombay Stock Exchange Limited

Floor 25, P.J. Towers

Dalal Street

Mumbai 400 001

Kind Attn.: Mr. Subramaniam

The National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1, G Block

Bandra-Kurla Complex, Bandra (E)

Mumbai 400 051

Kind Attn.: Mr. Hari K.

Dear Madam/Sir,

Sub: Revised Press Release for the audited financial results for the quarter and accounting year ended 31st December, 2010

Ref:- Our letter no. PPL/CS/SE/1412/2011 dated 1st April, 2011

We are submitting herewith Revised Press Release for the audited financial results for the quarter and accounting year ended 31st December, 2010. We may inform you that due to some typographical error the Basis EPS was wrongly specified as "for the quarter" instead "for the year".

Kindly take on record the duly corrected Press Release. The inconvenience caused is deeply regretted.


This is for the information of the Exchange and members thereof.

Kindly take the same on record and oblige.

Thanking You

Yours Sincerely

For PLETHICO PHARMACEUTICALS LIMITED


AMRISH CHOURASIA
COMPANY SECRETARY

Encl. : As above

PLETHICO PHARMACEUTICALS LIMITED

Regd. Office : A.B. Road, Manglia - 453 771, Dist. - Indore (M.P.), +91-731-2806275, +91-731-2806271
Admn. Office : 37, Industrial Estate, Pologround, Indore 452 015 (M.P.) Tel.: +91-731-2422881/84
Fax : +91-731-2420938, 2421309
Corporate Office : Sabnam House, Plot No. A-15/16, Central Cross Road-B, M.I.D.C., Andheri (East),
Mumbai 400 093, INDIA Tel.: +91-22-66988301/302, Fax : +91-22-66988330/+91-22-66988300
Website : www.plethico.com **E-mail :** info@plethico.com, corporate@plethico.com



Plethico Pharmaceuticals announces FY 2010 Results

**Net Sales for the Year stands at Rs. 1518 crore, up 22% Y-o-Y;
Company announces dividend of 25%**

Mumbai, March 31st, 2011: Plethico Pharmaceuticals Limited (BSE:532739: PLETHICO), a leading global healthcare and pharmaceutical company with a strong emphasis on the herbal and nutraceutical segments, today announced its financial results for FY 2010, ending December 31st, 2010.

Consolidated financial highlights for the year ending December 31st, 2010

- Consolidated Revenues stood at Rs 1,518 cr; an increase of 22% over the previous fiscal
- EBITDA Margin stood at 20.7% as against 19.4% for FY 09 ; an increase of 130 bps
- Consolidated Net Profit for the year stands at Rs 244.4 cr as against Rs. 216.9 cr of FY 09
- Basic EPS for the year stood at Rs 71.7 ; an increase of 13% over FY 09
- The Company has declared a dividend of 25% on a face value of Rs. 10 per share.

Commenting on the results, Mr. Shashikant Patel, Chairman and Managing Director, Plethico Pharmaceuticals Ltd., said, “We are extremely delighted with the performance of the Company in the last fiscal. Revenues grew by 22% while EBITDA margins also showed an improvement of 130 bps. The revenue uptick was a result of our geographic diversification strategy that we put in place while better cost efficiencies through outsourcing several products internationally helped improved our margins.”

He also added, “Our focused approach on nutraceutical products with a dedicated In-house promotion team has helped in the growth of our international business, Natrol from about US\$ 39 million in CY09 to US\$ 50 mn in CY 10. We are confident that cross selling of products from Natrol and Plethico across geographies will hold the business in good stead for the year forward.”

About Plethico

Plethico Pharmaceuticals Limited is a leading global healthcare and pharmaceutical company with a strong emphasis on the herbal and nutraceutical segments. Domestically, Plethico operates in the segments of Sports Nutrition, Confectionary and OTC, in India. The company’s robust product portfolio includes renowned, international brands including Travisil, Mountain Herbz, Coach’s Formula, Byte and Actifresh. Plethico is also a leading player in the Commonwealth of Independent States (CIS), Africa, South East Asia, Latin America and in the GCC for its Travisil range of products.

With the recent acquisition of Natrol – a leading manufacturer and marketer of branded nutritional products in the United States, Plethico has now expanded its global footprint to the regulated markets of the United States and Europe.

For further information, please contact:

Sanjay Pai Plethico Pharmaceuticals Tel: +91 22 6698 8301 Email: sanjay.pai@plethico.com	Niladri Mondal Christensen IR Tel: +91 99200 11558 Email: nmondal@christensenir.com
--	---